BioGaia AB (publ) (BIOGY)

Market Cap	1.20B +10.8%
Revenue (ttm)	155.20M +7.9%
Net Income	33.53M -6.2%
EPS	0.33 -6.4%
Shares Out	n/a
PE Ratio	35.69
Forward PE	27.57
Dividend	0.52 (4.77%)
Ex-Dividend Date	May 9, 2025

Volume	1,000
Average Volume	3,445
Open	11.00
Previous Close	10.35
Day's Range	11.00 - 11.00
52-Week Range	8.79 - 11.46
Beta	0.42
RSI	55.37
Earnings Date	Feb 12, 2026

About BioGaia AB

BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula and milk formula. The Adult Health segment provides gut health tablets, bone health tablet...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1990
• Employees: 238
• Stock Exchange: OTCMKTS
• Ticker Symbol: BIOGY

Financial Performance

In 2024, BioGaia AB's revenue was 1.42 billion, an increase of 9.73% compared to the previous year's 1.30 billion. Earnings were 351.39 million, a decrease of -3.82%.

Financial numbers in SEK